BBIO
BridgeBio Pharma Inc
66.50$
-0.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3,549.9% | -7,153.0% | -104.0% | 3,445.7% | -6,609.3% | -3,320.7% | -170.8% | -73.0% | -90.8% | -36.6% | -101.4% | -29.2% | -60.9% | |
| 40.1% | 90.8% | 0.8% | 72.6% | 56.3% | 23.2% | 1.1% | 1.2% | 1.2% | 0.9% | 0.9% | 0.4% | 0.8% | |
| 552.4% | 2,121.8% | 8.1% | 989.6% | 994.2% | 512.2% | 22.2% | 33.7% | 29.2% | 22.5% | 17.1% | 18.1% | 20.6% | |
| 32.0% | 1,259.5% | -106.7% | 11,367.1% | -78.4% | 220.1% | -99.6% | 17.6% | -3.3% | 32.2% | -64.1% | -3.8% | -12.4% | |
| 10.5% | 24.9% | 0.7% | 112.9% | 63.4% | 55.0% | 1.4% | 4.6% | 0.4% | 2.9% | 0.0% | 0.2% | 0.8% | |
| 921.1% | -3.8% | 10.8% | 140.2% | 1,399.2% | -55.0% | -1.4% | -11.8% | 3.7% | -8.9% | -22.0% | 7.3% | -4.8% | |
| -63.8% | -146.4% | -1.4% | -80.4% | -52.8% | -23.9% | -42.9% | -1.8% | 3.1% | -3.6% | -42.4% | -54.1% | -30.3% | |
| – | – | – | – | 0.0% | 8,500.5% | 99.5% | 271.3% | -248.6% | 0.0% | 325.2% | 0.0% | 46.6% | |
| 7,505.3% | -259.2% | 132.4% | -264.3% | 25.9% | 8,057.3% | 51.7% | 273.2% | -0.7% | -1.8% | 282.7% | -61.1% | 55.7% | |
| 4,876.5% | -7,415.9% | 39.2% | 3,321.7% | -5,184.2% | 4,681.5% | -120.5% | 188.4% | -88.1% | -47.0% | 159.3% | -82.9% | -9.9% | |
| -3,560.4% | -7,177.9% | -104.7% | 3,332.8% | -6,672.7% | -3,375.8% | -172.2% | -77.6% | -91.2% | -39.5% | -101.5% | -29.4% | -61.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.